Characteristics n  
Gender, n (%) of male 364 293 (81)
Mean age (SD), years 358 45 (9)
Mean weight (SD), kg 361 65 (13)
HIV transmission, n (%)    
Sexual 364 281 (77)
Drug addiction 364 53 (15)
Blood transfusion or blood exposure accidents 364 13 (4)
Other or unknown 364 17 (5)
CDC stage C, n (%) 362 189 (52)
HBV coinfection (HBsAg), n (%) 364 15 (4)
HCV coinfection (anti-HCV), n (%) 364 60 (17)
Mean (SD) delay since HIV infection diagnosis, years 266 15 (4)
Median (range) number of prior antiretroviral drugs 352 11 (1–21)
Median (range) CD4 cells/mm3 338 155 (1–937)
< 200 cells/mm3, n (%) 338 207 (61)
≥ 200 cells/mm3, n (%) 338 131 (39)
Median (range) HIV-1 RNA, log10 copies/mL 333 4.7 (1.3–6.5)
Genotypic sensitivity score, n (%)*    
0 327 49 (15)
1 327 129 (39)
2 327 125 (38)
3 327 22 (7)
4 327 2 (1)
*The number of active antiretroviral molecules was assessed in 327 patients with
genotypes available at inclusion (3TC/FTC was not taken into account).
Table 1: Characteristics of cohort patients at inclusion.